Mayinglong Pharmaceutical Group Co Ltd Market Cap ($1.58 Billion)
Market Cap & Net Worth: Mayinglong Pharmaceutical Group Co Ltd (600993)
Mayinglong Pharmaceutical Group Co Ltd market cap. Mayinglong Pharmaceutical Group Co Ltd (SHG:600993) has a market capitalization of $1.58 Billion (CN¥10.80 Billion) as of November 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #6779 globally and #1364 in its home market, demonstrating a 4.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayinglong Pharmaceutical Group Co Ltd's stock price CN¥25.05 by its total outstanding shares 431053891 (431.05 Million). Also see 600993 cash flow metrics for how efficiently the company converts equity into cash flow.
Mayinglong Pharmaceutical Group Co Ltd Market Cap History (2015–2026)
Mayinglong Pharmaceutical Group Co Ltd market cap history from 2015 to 2026. Data shows growth from $1.27 Billion to $1.58 Billion (2.63% CAGR). Check 600993 live share price for real-time trading data and today's change.
Mayinglong Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayinglong Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Mayinglong Pharmaceutical Group Co Ltd annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.46x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 0.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.04x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 3.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.16 Billion | $2.10 Billion | $250.24 Million | 0.55x | 4.63x |
| 2017 | $1.20 Billion | $1.75 Billion | $320.05 Million | 0.68x | 3.75x |
| 2018 | $797.62 Million | $2.20 Billion | $176.21 Million | 0.36x | 4.53x |
| 2019 | $1.05 Billion | $2.71 Billion | $359.97 Million | 0.39x | 2.91x |
| 2020 | $1.22 Billion | $2.79 Billion | $419.06 Million | 0.44x | 2.91x |
| 2021 | $1.76 Billion | $3.39 Billion | $464.59 Million | 0.52x | 3.79x |
| 2022 | $1.41 Billion | $3.53 Billion | $478.57 Million | 0.40x | 2.94x |
| 2023 | $1.53 Billion | $3.14 Billion | $443.25 Million | 0.49x | 3.44x |
| 2024 | $1.65 Billion | $3.73 Billion | $528.09 Million | 0.44x | 3.12x |
| 2025 | $1.77 Billion | $3.87 Billion | $581.49 Million | 0.46x | 3.04x |
Competitor Companies of 600993 by Market Capitalization
Companies near Mayinglong Pharmaceutical Group Co Ltd in the global market cap rankings as of November 7, 2026. Also see 600993 asset base for a full breakdown of the balance sheet.
Key companies related to Mayinglong Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Mayinglong Pharmaceutical Group Co Ltd (2015–2026)
Market capitalization of Mayinglong Pharmaceutical Group Co Ltd from 2015 to today. Between 2015 and today, Mayinglong Pharmaceutical Group Co Ltd's market cap moved from $1.27 Billion to $ 1.58 Billion, with a yearly change of 2.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.58 Billion | -10.54% |
| 2025 | CN¥1.77 Billion | +7.24% |
| 2024 | CN¥1.65 Billion | +7.98% |
| 2023 | CN¥1.53 Billion | +8.45% |
| 2022 | CN¥1.41 Billion | -20.17% |
| 2021 | CN¥1.76 Billion | +44.29% |
| 2020 | CN¥1.22 Billion | +16.44% |
| 2019 | CN¥1.05 Billion | +31.45% |
| 2018 | CN¥797.62 Million | -33.48% |
| 2017 | CN¥1.20 Billion | +3.55% |
| 2016 | CN¥1.16 Billion | -8.51% |
| 2015 | CN¥1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Mayinglong Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.58 Billion USD |
| MoneyControl | $1.58 Billion USD |
| MarketWatch | $1.58 Billion USD |
| marketcap.company | $1.58 Billion USD |
| Reuters | $1.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more